Skip to content
AnalystLens

Idex Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed October 30, 2024
Period End
September 30, 2024
Security
IEX
One revenue dollarkept$0.15
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation's Form 10-Q for the quarter ended September 30, 2024 shows third-quarter net sales of $798.2 milliona, up 1% from $793.4 million a year earlier, with organic net sales flat.

Net income attributable to IDEX fell 43% to $119.1 millionb, and diluted EPS was $1.57 versus $2.75. The company attributes the softness largely to continued market headwinds in the Health & Science Technologies segment, which saw lower volumes, partly offset by price capture and productivity across segments. Adjusted EBITDA was $214.3 million versus $225.5 million, and adjusted diluted EPS was $1.90 versus $2.12.

The prior-year quarter included a $93.8 millionc pre-tax gain on the sale of Micropump, which explains much of the decline in reported earnings. For the nine months, net sales were $2,405.9 million, down 3% from $2,485.0 million, and organic net sales decreased 3%. Diluted EPS was $5.02 versus $6.42.

Operating cash flow was $495.5 milliond and free cash flow was $445.9 million, roughly flat with the prior year. The most significant event of the period was the September 5, 2024 acquisition of Mott Corporation for cash consideration of $986.2 million, funded with cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from new 4.950% Senior Notes due 2029. Total borrowings rose to $2,087.4 million from $1,333.3 million at year-end 2023.

Liquidity remains solid, with $633.2 million of cash and cash equivalents, $436.7 million of available Revolving Facility capacity, and compliance with financial covenants (interest coverage of 18.19 to 1 versus a 3.0 to 1 minimum, and leverage of 2.39 to 1 versus a 3.50 to 1 maximum). Subsequent to quarter end, the company repaid $69.1 million under the Revolving Facility and the remaining $25.0 million under the Term Facility. Credit ratings were reaffirmed by S&P (BBB, stable), Moody's (Baa2, stable) and Fitch (BBB+, stable).

Key Highlights

  1. Third-quarter net sales of $798.2 million, up 1% year over year, with organic net sales flat; nine-month net sales of $2,405.9 million, down 3%.
  2. Third-quarter net income attributable to IDEX of $119.1 million, down 43% from $209.1 million, largely reflecting the prior-year $93.8 million gain on the Micropump sale; adjusted net income was $144.1 million versus $160.6 million.
  3. Adjusted EBITDA of $214.3 million in the quarter versus $225.5 million a year earlier, with adjusted EBITDA margin of 26.9% versus 28.4%.
  4. Acquired Mott Corporation on September 5, 2024 for cash consideration of $986.2 million, expanding the Health & Science Technologies segment's applied material science capabilities.
  5. Total borrowings increased to $2,087.4 million from $1,333.3 million at December 31, 2023, following the issuance of $500.0 million of 4.950% Senior Notes due 2029 and Revolving Facility draws.
  6. Free cash flow of $445.9 million for the nine months, compared with $447.4 million in the prior-year period; no share repurchases were made in 2024, leaving $539.7 million of authorization remaining.
  7. Health & Science Technologies segment net sales declined 8% for the nine months, with organic net sales down 10%, reflecting broad-based market softness.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2024, Idex kept $0.15.

  1. Revenue$798.2M100.0%
  2. Cost of revenue−$444.3M55.7%
  3. Gross profit$353.9M44.3%
  4. Operating costs−$185.9M23.3%
  5. Operating income$168.0M21.0%
  6. Interest, other & tax−$48.9M6.1%
  7. Net income$119.1M14.9%
Computed from 10-QQ3 FY2024filed October 30, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$798.20M$793.40M+0.6%
Cost of Revenue$444.30M$443.80M+0.1%
Gross Profit$353.90M$349.60M+1.2%
SG&A Expenses$182.90M$165.90M+10.2%
Operating Income$168.00M$179.60M−6.5%
Net Income$119.10M$209.00M−43.0%
EPS (Basic)$1.57$2.76−43.1%
EPS (Diluted)$1.57$2.75−42.9%
Shares Outstanding (Basic)75.70M75.60M+0.1%
Shares Outstanding (Diluted)75.90M75.90M0.0%

Frequently Asked Questions

  1. Why did net income fall so sharply in the third quarter of 2024?

    Net income attributable to IDEX declined 43% to $119.1 million from $209.1 million. The prior-year quarter included a $93.8 million pre-tax gain on the sale of Micropump, Inc., while the 2024 quarter recorded a $0.6 million downward adjustment to the Alfa Valvole gain. Excluding these items, adjusted net income fell 10% to $144.1 million from $160.6 million.

  2. How did the Mott acquisition affect the company's balance sheet and financing?

    Mott was acquired for $986.2 million net of cash acquired, funded with $211.9 million of cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from the 4.950% Senior Notes due 2029. Goodwill of $480.3 million and intangible assets of $415.8 million were recognized, and long-term borrowings rose to $2,075.1 million.

  3. What drove the weakness in the Health & Science Technologies segment?

    The filing states that market softness in the segment resulted in lower sales volumes. For the nine months, segment net sales decreased 8% and organic net sales decreased 10%, and Adjusted EBITDA margin declined to 26.8% from 27.8%, which the company attributed to lower volume, higher employee-related costs and unfavorable mix, partly offset by price/cost and productivity.

  4. Is the company in compliance with its debt covenants and how much liquidity does it have?

    Yes. At September 30, 2024, the interest coverage ratio was 18.19 to 1 against a minimum of 3.0 to 1, and the leverage ratio was 2.39 to 1 against a maximum of 3.50 to 1. The company held $633.2 million of cash and cash equivalents, with $436.7 million of Revolving Facility availability after $360.6 million of borrowings and $2.7 million of letters of credit.

  5. What were the key subsequent events after the quarter ended?

    During October 2024, the company repaid $69.1 million of the $360.6 million outstanding under the Revolving Facility and the remaining $25.0 million outstanding under the Term Facility, reducing near-term borrowings.